Scancell Release: SCIB1 Immunobody DNA Vaccine Phase I Trial Commences
6/15/2010 6:59:45 AM
NOTTINGHAM, UK--(BUSINESS WIRE)--Scancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer vaccines, today announces the enrolment and treatment of the first patient in its multicentre Phase I clinical trial of SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma. The trial will evaluate the safety and tolerability of SCIB1 in patients with late stage melanoma.
comments powered by